Metastatic Hormone-Sensitive Prostate Cancer: Benefits and Risks of Current and Emerging Treatment Options

Jointly provided by


This activity is supported by independent educational grants from Astellas and Pfizer, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Release date: 8/11/2020

Expiration date: 8/11/2021

Estimated time to complete: 1.0 hour


Prostate cancer is the most common cancer in men in the U.S.; in 2018, more than 3 million men were living with the disease. For men in whom prostate cancer is local or regional, 5-year survival approaches 100%. For those with metastatic hormone-sensitive prostate cancer (mHSPC), however, the 5-year survival rate is only 30%. Androgen deprivation therapy (ADT) has long been a treatment mainstay for mHSPC but may be associated with cardiovascular (CV) risks. Recently, the ADT treatment paradigm for mHSPC was modified based on clinical trials demonstrating the effectiveness of docetaxel or abiraterone (with prednisone) in combination with ADT in improving survival in patients with mHSPC. Several other therapies combined with ADT are also available.

In this Virtual Practice, you will meet with two prostate cancer patients—reviewing medical records, assessing symptoms, ordering tests, and evaluating the risks and benefits of different therapeutic options as you develop a treatment plan with the best chance of optimizing outcomes.

Following each case presentation, you will have the opportunity to play Cranium Challenge, a rapid-fire categorization game that puts your clinical knowledge to the test.


Alicia K. Morgans, MD, MPH—Program Chair
Associate Professor
Northwestern University
Chicago, Illinois

Tanya B. Dorff, MD
Associate Clinical Professor of Medicine
City of Hope
Duarte, California

Neal D. Shore, MD, FACS
Medical Director, CPI
Caroline Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Target Audience

This activity has been developed to meet the educational needs of urologists, medical oncologists, and other health care providers who treat patients with prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Weigh the benefits and CV risks associated with treatments when providing evidence-based care for patients with mHSPC
  • Evaluate current and emerging data on treatment advances and appropriately incorporate into practice newer strategies for managing patients with mHSPC

Accreditation Statement 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement 

The University of Cincinnati designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CE activity content over which the individual has control. Relationship information appears below.


Tanya B. Dorff, MD, has disclosed the following relevant financial relationships:
Advisory Board: Advanced Accelerator Applications, Bayer, Bristol-Myers Squibb, Exelixis, Seattle Genetics
Consultant: Dendreon, Seattle Genetics
Alicia K. Morgans, MD, MPH, has disclosed the following relevant financial relationships:
Advisor: Astellas, AstraZeneca, Bayer, Janssen, Sanofi

Consultant: Astellas, AstraZeneca, Bayer, Sanofi
Neal D. Shore, MD, CPI, has disclosed the following relevant financial relationships:
Research/Consulting: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Dendreon, Foundation Med, Janssen, Merck, Myovant, Nymox, Pfizer, Sanofi-Genzyme, Tolmar

University of Cincinnati
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Denise LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Heather Rafa, Program Manager, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The University of Cincinnati; RedMedEd; Astellas and Pfizer, Inc.; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., do not recommend the use of any agent outside the labeled indications. 


The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition. 

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati; RedMedEd; Astellas and Pfizer, Inc.; or Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity content in both modules, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 75% or greater) and program evaluation. Certificates can be printed immediately. 

Contact Information

For questions regarding CME credit, contact the University of Cincinnati at 513.558.7277 or

For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or

Hardware/Software Requirements

  • Apple iPad, iPad mini (iOS 11 or higher), iPhones (iOS 11 or higher), and Android phones (4.0.3 or higher) with an Internet connection
    • Internet browsers: Chrome, Firefox, Safari
  • A computer with an Internet connection
    • Internet browsers (PC): Chrome, Firefox, Microsoft Edge, Internet Explorer 11 or higher
    • Internet browsers (Mac): Chrome, Firefox, Safari 13 or higher


This website is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. CME credit for this activity is provided by the University of Cincinnati. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to the University of Cincinnati so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. The information you provide on this site may be used to contact you about your CME credit or other relevant educational activities provided through the University of Cincinnati or RedMedEd. For more information, contact UC CME at or

For more information about the privacy policy of the University of Cincinnati, please visit


©2020. This CME-certified program is held as copyrighted by the University of Cincinnati and RedMedEd. Through this notice, the University of Cincinnati and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.